• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of pain and symptom management. >Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain.
【24h】

Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain.

机译：将患有进行性骨转移的乳腺癌患者转换为第三代双膦酸盐：使用癌症治疗性骨痛功能评估来评估影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Because bone metastases cause significant pain, we developed a questionnaire to evaluate its nature, severity, and impact. This 16-item questionnaire is the Functional Assessment of Cancer Therapy-Bone Pain (FACT-BP). We also developed a 13/18-item questionnaire, the Functional Assessment of Chronic Illness Therapy-Treatment Satisfaction-Bone Treatment Convenience and Satisfaction Questionnaire (FACIT-TS-BTCSQ), to evaluate patients' expectations and acceptance of bone-specific therapies. We evaluated the performance of these scales in two clinical trials. In both trials, we enrolled patients with metastatic breast cancer, who had progressive bone metastases despite first-line therapy with pamidronate or clodronate. We administered intravenous zoledronic acid to 31 patients in one trial and oral ibandronate to 30 patients in the other. Patients completed the FACT-BP questionnaire and FACIT-TS-BTCSQ at baseline, then at Weeks 4, 8, and 12. The FACT-BP scale showed good internal consistency reliability [Cronbach's alpha (alpha)=0.93-0.96]. There was evidence of construct validity, and known-group validity was supported by score shifts in the anticipated direction (Cohen's d effect size=0.36). The FACT-BP score reflected clinical change as evidenced by differences in performance status. This cross-sectional anchor-based criterion suggested reasonable clinically important differences (effect size=0.36). The FACIT-TS-BTCSQ showed good internal consistency reliability for treatment expectation (alpha=0.87) and treatment experience (alpha's=0.89-0.92). The FACT-BP scale is meaningful and appears appropriate for broader use. The assessment of satisfaction (FACIT-TS-BTCSQ) raised questions that will require further research.
机译：因为骨转移会引起严重的疼痛，所以我们开发了一份问卷来评估其性质，严重性和影响。这份16项问卷是癌症骨痛功能评估（FACT-BP）。我们还开发了一项13/18项调查问卷，即“慢性病治疗-满意程度-骨治疗便利性和满意度调查表”（FACIT-TS-BTCSQ）的功能评估，以评估患者对骨特异性疗法的期望和接受程度。我们在两项临床试验中评估了这些量表的性能。在这两项试验中，我们纳入了转移性乳腺癌患者，这些患者尽管接受了帕米膦酸或氯膦酸盐的一线治疗，但仍具有进行性骨转移。我们在一项试验中对31名患者进行了静脉注射唑来膦酸的治疗，在另一项试验中对30名患者进行了口服伊班膦酸的治疗。患者在基线，然后在第4、8和12周完成FACT-BP问卷和FACIT-TS-BTCSQ。FACT-BP量表显示出良好的内部一致性信度[Cronbach's alpha（α）= 0.93-0.96]。有结构效度的证据，已知群体效度得到预期方向得分变化的支持（Cohen d效应大小= 0.36）。 FACT-BP评分反映了临床变化，表现状态差异证明了这一点。该基于锚的横截面标准建议合理的临床重要差异（效应量= 0.36）。 FACIT-TS-BTCSQ对治疗预期（α= 0.87）和治疗经验（α's = 0.89-0.92）显示出良好的内部一致性可靠性。 FACT-BP量表是有意义的，似乎适合更广泛的使用。满意度评估（FACIT-TS-BTCSQ）提出了需要进一步研究的问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号